A pilot study to evaluate the efficacy of 3 doses of L-carnitine supplementation in chronic kidney disease patients with complications caused by carnitine deficiency

A pilot study to evaluate the efficacy of 3 doses of L-carnitine supplementation in chronic kidney disease patients with complications caused by carnitine deficiency - "CENTRAL"

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008585

Enrollment

150

Registered

2012-08-01

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

L-carnitine 300mg L-carnitine 600mg L-carnitine 1200mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients who are thought to be deficient of carnitine 2)patients who have more than 2 symptoms as belows: .renal anemia regardless of ESA .muscle cramps .fatigue .arrhythmia .cardiac hypertrophy 3)no limitation of age and sex 4)ability to provide written informed consent

Exclusion criteria

Exclusion criteria: 1)history of allergy against this drug 2)ability of oral administration 3)alcoholic or drug abuse 4)cancer 5)patients who are judged to be inappropriate to this study

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms due to carnitine deficiency (muscle cramps, fatigue and anemia)	—

Secondary

Measure	Time frame
reduction of the dose of ESA, improvement of anemia, frequency of administration of shakuyakukanzoto, change in muscle mass, improvement of cardiac function, adverse events	—

Countries

Japan

Contacts

Public ContactTaichi Nakamura

Yokohama City Minato Red Cross Hospital Internal Medicine, Nephrology

045-628-6100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026